Skip to main content

Table 6 Multivariate analysis in NSCLC

From: The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

 PFSOS
UnivariateMultivariateUnivariateMultivariate
HR95% CIp valueHR95% CIp valueHR95% CIp valueHR95% CIp value
ECOG
 0 or 11.0 0.0051.0 0.0031.0 0.0061.0 0.015
 2 or 32.3161.281–4.187 3.9451.573–9.896 2.4641.288–4.711 3.8941.301–11.660 
ICI
 Nivolumab1.0 0.891   1.0 0.3631.0 0.039
 Pembrolizumab1.1150.716–1.7360.631   1.310.790–2.1730.2953.3421.187–9.4110.022
 Others1.0430.595–1.8280.884   0.8010.410–1.5640.5162.6510.676–10.4030.162
Stage
 III1.0 0.1011.0 0.1411.0 0.2161.0 0.127
 IV3.2410.794–13.223 4.6450.601–35.859 2.4390.593–10.030 5.7470.610–54.146 
Number of metastatic organ
 0 or 11.0 0.0071.0 0.0781.0 < 0.0011.0 0.014
 ≥ 21.7541.170–2.630 1.6810.943–2.996 2.7321.697–4.397 2.4011.193–4.830 
Brain metastasis
 No1.0 0.5021.0 0.0261.0 0.9791.0 0.112
 Yes0.8320.485–1.425 0.3730.157–0.890 1.0080.553–1.836 0.3980.128–1.241 
Number of treatment line
 1st1.0 0.064   1.0 0.324   
 2nd1.4840.911–2.4180.113   1.2450.717–2.1630.437   
 ≥ 3rd1.8551.102–3.1210.02   1.5680.871–2.8220.134   
Clinical trial
 Yes1.0 0.0321.0 0.0111.0 0.0181.0 0.031
 No1.5541.039–2.324 2.351.217–4.537 1.7821.104–2.877 3.271.116–9.584 
Histologic subtype
 Adenocarcinoma1.0 0.768   1.0 0.855   
 Squamous cell carcinoma1.0640.703–1.610    0.9560.59.-1.542    
PD-L1
 Negative  0.2261.0 0.0641.0 0.3961.0 0.024
 Low1.7230.776–3.8270.1810.9520.372–2.4400.9191.8390.676–4.9990.2330.8020.229–2.8170.731
 High1.1650.546–2.4860.6930.4470.179–1.1170.0851.3290.515–3.4330.5570.2180.055–0.8660.030
EGFR
 Negative1.0 0.1961.0 0.0611.0 0.3761.0 0.072
 Positive1.5540.796–3.031 2.5740.956–6.929 1.4010.664–2.956 2.9640.906–9.695 
Antibiotics before ICI
 No1.0 0.0011.0 0.0061.0 < 0.0011.0 0.001
 Yes1.9481.310–2.898 2.3791.281–4.418 2.4761.568–3.911 3.8341.736–8.469